A once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection. What will really matter in the long run? That’s the question we tackle each year as ...

A NEW injection that could prevent HIV infection has successfully completed an early safety trial, according to a report in ...

To manage risk, investors should diversify their stock portfolio across industries and this could be the stock to study in the pharmaceutical sector for the long haul.

Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...

In a ceremony held last month, the 2024 Louisa Gross Horwitz Prize was awarded to Wesley Sundquist, PhD, Leo T. and Barbara K ...

The BRAVE-AA-PEDS trial found that once-daily baricitinib significantly improved hair regrowth on the scalp, eyebrows, and ...

On February 18, 2025, Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications ...